News

In China's rapidly evolving fine chemicals and pharmaceutical ingredients industry, Jiangxi Brother Pharmaceutical Co., Ltd. has emerged as a comprehensive manufacturer serving both the flavor & fragrance and pharmaceutical sectors. Backed by Brother Enterprises Holding Co., Ltd., the company operates an integrated production base in Jiujiang, Jiangxi Province, combining advanced chemical synthesis capabilities with internationally recognized quality systems.Its three flagship products—Vanillin, Ethyl Vanillin, and Iohexol—have become essential raw materials across two completely different markets. Vanillin and Ethyl Vanillin are widely used throughout the global food and fragrance supply chain, while Iohexol serves as a critical active pharmaceutical ingredient (API) for modern medical imaging. Together, these products demonstrate the company's unique ability to bridge everyday consumer applications with high-end healthcare.At first glance, food flavorings and pharmaceutical contrast media appear to belong to entirely different industries. So how can one manufacturer produce both?The answer lies in the common technological foundation of fine chemical manufacturing. Whether producing aromatic flavor compounds or iodine-containing pharmaceutical APIs, the essential processes include precision chemical synthesis, high-purity purification, and rigorous quality control.Leveraging its integrated manufacturing base in Jiujiang, Jiangxi Brother Pharmaceutical has established dedicated production systems. Food-grade flavor ingredients are manufactured in standard clean workshops, while pharmaceutical APIs are produced in independent GMP-compliant facilities. Both production lines benefit from shared R&D resources, distillation technology, analytical laboratories, and supply chain management, allowing the company to improve efficiency while maintaining strict quality standards.Today, the company's products are exported across Europe and Asia and comply with internationally recognized standards including USP, EP, and FCC. It has also obtained European CEP certification and completed pharmaceutical registrations in countries such as India and Türkiye, strengthening both domestic and international market competitiveness.CAS No.: 121-33-5Vanillin is the world's most widely used synthetic flavor compound. The familiar creamy vanilla aroma found in baked goods, chocolate, ice cream, dairy products, and countless consumer products is largely derived from vanillin.Jiangxi Brother Pharmaceutical produces food-grade vanillin with a purity of ≥99.5%, meeting international pharmacopoeia standards. The product appears as white crystalline powder with a clean, natural vanilla aroma and minimal chemical odor.Main ApplicationsBakery products and confectioneryChocolate and dairy productsIce cream and beveragesToothpaste and personal care productsFragrances and household productsPharmaceutical flavor masking and intermediatesSupported by large-scale synthetic production technology, the company's vanillin capacity ranks among the industry's leading manufacturers, helping its parent company maintain a significant share of the global vanillin market and becoming an important supplier within the international flavor industry.CAS No.: 121-32-4Often regarded as the premium version of vanillin, Ethyl Vanillin shares a similar molecular structure but delivers an aroma intensity approximately three to four times stronger than conventional vanillin. It offers richer creamy notes, longer-lasting fragrance, and greater stability, making it one of the most valuable synthetic flavor ingredients.Jiangxi Brother Pharmaceutical supplies Ethyl Vanillin with a purity of ≥99.0%, available in flexible packaging ranging from 1 kg laboratory packs to 25 kg industrial drums, meeting the purchasing needs of both specialty fragrance manufacturers and large-scale food producers.Typical ApplicationsPremium chocolate productsHigh-end bakery productsLuxury home fragrancesTobacco flavoringAnimal feed attractantsCompared with standard vanillin, Ethyl Vanillin exhibits better heat resistance, making it especially suitable for high-temperature baking processes where aroma retention is essential.Together, Vanillin and Ethyl Vanillin form complementary product lines. Vanillin serves the large-volume, cost-effective market, while Ethyl Vanillin targets premium applications requiring stronger and more persistent aroma performance. These two products have become key revenue drivers for Jiangxi Brother Pharmaceutical's flavor ingredients business.While Vanillin and Ethyl Vanillin are closely connected with everyday consumer products, Iohexol represents Jiangxi Brother Pharmaceutical's technological strength in the high-end pharmaceutical industry.Patients undergoing enhanced CT scans, angiography, or urinary tract imaging are often administered contrast agents whose core active ingredient is Iohexol.As a non-ionic, water-soluble iodinated contrast agent API, Iohexol offers low toxicity, excellent imaging quality, rapid metabolism, and significantly fewer adverse reactions compared with traditional ionic contrast agents. Today, it has become one of the preferred contrast media ingredients used in clinical imaging worldwide.Unlike food flavor production, manufacturing Iohexol requires strict compliance with Good Manufacturing Practice (GMP) standards. Every production stage—from synthesis to purification, sterile processing, and batch testing—is conducted under tightly controlled pharmaceutical manufacturing conditions.In 2024, Jiangxi Brother Pharmaceutical received domestic marketing approval for its Iohexol API, further expanding the group's contrast media portfolio alongside products such as Iopamidol and Ioversol, establishing a comprehensive range of iodinated contrast agent APIs.Industry SignificanceFor many years, high-end iodinated contrast media APIs relied heavily on imported suppliers, resulting in relatively high costs.The commercialization of domestically manufactured Iohexol by Jiangxi Brother Pharmaceutical helps strengthen China's pharmaceutical supply chain, reduce production costs for downstream pharmaceutical companies, improve healthcare affordability, and enhance the international competitiveness of Chinese pharmaceutical ingredients through exports supported by global regulatory certifications.Managing products for both food and pharmaceutical industries requires exceptionally strict quality systems. Jiangxi Brother Pharmaceutical has therefore established independent quality management frameworks for each production line while maintaining shared technological advantages.Flavor Ingredient ProductionManufactured under food safety regulationsHeavy metal and impurity monitoringCertified food production facilitiesCompliance with international food standardsPharmaceutical API ProductionIndependent GMP-compliant cleanroomsDedicated production equipmentSegregated manufacturing areas to eliminate cross-contaminationComplete batch traceability and analytical documentationCompliance with global pharmaceutical regulatory inspectionsShared Manufacturing AdvantagesProprietary green synthesis technologiesReduced emissions and environmental impactHigher production efficiencySustainable manufacturing practices aligned with global environmental requirementsAs competition intensifies throughout the chemical industry, commodity chemicals continue to face excess capacity and shrinking margins. Jiangxi Brother Pharmaceutical has chosen a different path by concentrating on technically demanding, high-value specialty products instead of expanding into low-end commodity chemicals.The comforting vanilla aroma found in everyday foods and the pharmaceutical ingredients that support advanced medical imaging may seem unrelated. However, both originate from the same foundation of precision fine chemical manufacturing.By combining stable flavor ingredient production with high-value pharmaceutical APIs, Jiangxi Brother Pharmaceutical has successfully established a dual-engine business model—generating steady cash flow through globally recognized flavor ingredients while advancing into technologically sophisticated pharmaceutical markets.From tiny crystals that enhance the flavor of food to pharmaceutical ingredients that support accurate medical diagnosis, the company's three flagship products demonstrate that fine chemicals are far more than industrial compounds—they quietly improve everyday life while helping safeguard modern healthcare. Mobile: +8615371019725E-mail: sales7@bouling-chem.comWebsite: www.brother-pharmaceutical.com

In China's vitamin, fine chemicals, and pharmaceutical industries, three closely connected companies have quietly established themselves among the industry's leading players through an integrated value chain and long-term strategic development. They are Brother Enterprises Holding Co., Ltd., Jiangsu Brother Vitamins Co., Ltd., and Jiangxi Brother Pharmaceutical Co., Ltd.For many industry professionals and international buyers, these similarly named companies can be confusing at first glance. Although they share the same corporate heritage, each serves a distinct role within the Brother Technology ecosystem. Together, they form a complete industrial network spanning strategic investment, vitamin manufacturing, and high-value pharmaceutical production.This article explores how these three companies are connected, what differentiates their businesses, and why their coordinated development has become a competitive advantage in the global fine chemical and pharmaceutical markets.All three companies belong to the Brother Technology industrial system and operate under a clear organizational structure consisting of a strategic holding company supported by two specialized manufacturing bases.Brother Enterprises Holding Co., Ltd. – The Strategic Management PlatformAs the group's holding company, Brother Enterprises Holding Co., Ltd. is responsible for corporate strategy, investment, financing, capital management, global resource allocation, and long-term business planning. Rather than engaging directly in manufacturing, it oversees the development of the group's industrial operations, including infrastructure investment, capacity expansion, supply chain coordination, regulatory compliance, and risk management across both the Jiangsu and Jiangxi production bases.Through centralized management, the holding company is able to coordinate major R&D investments, optimize global raw material procurement, strengthen capital market operations, and improve overall operational efficiency, providing the strategic foundation for the group's sustainable growth.Jiangsu Brother Vitamins Co., Ltd. – The Group's Vitamin Manufacturing BaseEstablished in May 2005 and located in Dafeng Marine Economic Development Zone, Yancheng, Jiangsu Province, Jiangsu Brother Vitamins Co., Ltd. serves as the group's long-established vitamin production base and is a wholly owned subsidiary of Brother Technology.If the holding company represents the group's strategic headquarters, Jiangsu Brother Vitamins forms the industrial backbone of the organization.For more than two decades, the company has specialized in vitamin manufacturing, focusing primarily on Vitamin B1, Vitamin B3, and Vitamin K3. Its products are widely used in feed additives, food additives, and pharmaceutical intermediates. Recognized as both a National High-Tech Enterprise and a "Little Giant" Specialized and Innovative Enterprise, the company emphasizes large-scale production, cost efficiency, and reliable global supply.Compared with the group's pharmaceutical operations, the Jiangsu facility concentrates on high-volume vitamin manufacturing, serving major feed and food companies worldwide while providing a stable source of revenue for the group.Jiangxi Brother Pharmaceutical Co., Ltd. – Driving High-Value Pharmaceutical GrowthFounded in 2014 in Pengze County, Jiangxi Province, Jiangxi Brother Pharmaceutical Co., Ltd. occupies an industrial park covering approximately 2,000 acres and serves as the group's advanced pharmaceutical manufacturing base. It is also a wholly owned subsidiary of Brother Technology.While the Jiangsu facility focuses on large-scale vitamin production, Jiangxi Brother Pharmaceutical targets high-value pharmaceutical and specialty chemical markets. Its business portfolio includes premium vitamin derivatives, flavor and fragrance ingredients, iodinated contrast media, specialty APIs, and chemical catalysts.Supported by Jiangxi's integrated chemical industry infrastructure, the company has earned multiple recognitions, including National Green Factory status, Provincial Enterprise Technology Center certification, and a Provincial Academician Workstation. Combining advanced manufacturing with sustainable production practices, the company achieved operating revenue exceeding RMB 1.656 billion in 2025 and employs more than 1,700 people, making it a key platform for Brother Technology's transformation toward innovation-driven pharmaceutical manufacturing.Many chemical manufacturers focus either on commodity chemicals or pharmaceutical products, often resulting in fragmented supply chains and higher production costs.The Brother group adopts a different approach by assigning distinct responsibilities to each business entity while integrating them into a unified industrial ecosystem.Brother Enterprises Holding Co., Ltd. provides strategic leadership, oversees capital allocation, regulatory compliance, international expansion, and long-term investment planning.Jiangsu Brother Vitamins Co., Ltd. manufactures large-scale vitamin products and essential intermediates that are supplied to both external customers and internal pharmaceutical operations.Jiangxi Brother Pharmaceutical Co., Ltd. transforms these intermediate materials into higher-value pharmaceutical APIs, iodinated contrast agents, specialty chemicals, and flavor ingredients for premium global markets.In simple terms, Jiangsu manufactures the foundational materials, Jiangxi produces high-value pharmaceutical products, and the holding company coordinates the group's overall development.This integrated model enables greater raw material security, optimized production costs, stronger technical collaboration, and improved resilience against market volatility and supply chain disruptions.Success in both fine chemicals and pharmaceuticals depends not only on production capacity but also on continuous technological innovation.The three companies share a unified research and development system consisting of a corporate research institute, specialized business-unit R&D centers, and technical teams located within each manufacturing facility.The group collaborates extensively with leading research institutions, including Tsinghua University, Zhejiang University, Sichuan University, and the Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, among many others. These partnerships focus on advanced synthesis technologies, green catalytic processes, pharmaceutical purification techniques, and sustainable manufacturing.At the same time, the two manufacturing bases maintain distinct research priorities.The Jiangsu facility focuses on improving vitamin production efficiency, reducing manufacturing costs, and optimizing large-scale industrial processes.The Jiangxi facility concentrates on pharmaceutical intermediates, iodinated contrast media, innovative APIs, environmentally friendly production technologies, and regulatory compliance for global pharmaceutical markets.By sharing research resources while specializing in different technological directions, the group minimizes duplication, accelerates innovation, and supports its transition from a traditional chemical manufacturer to a modern innovation-oriented pharmaceutical enterprise.Within the chemical and pharmaceutical industries, companies with similar names often exist because of corporate restructuring, tax planning, or business separation, frequently creating confusion among customers.The Brother group's organizational strategy offers a valuable example of how specialization and integration can work together.First, each company maintains a clearly defined business focus, separating strategic management, bulk manufacturing, and high-value pharmaceutical production to improve operational efficiency and regulatory compliance.Second, vertical integration across the supply chain strengthens internal collaboration while reducing exposure to raw material price fluctuations and supply chain risks.Third, the group balances stable revenue from mature vitamin businesses with long-term investment in innovative pharmaceutical products, supporting both short-term profitability and sustainable growth.Beginning with the establishment of the Jiangsu vitamin manufacturing base in 2005, followed by the development of the holding platform and the launch of the Jiangxi pharmaceutical facility nearly a decade later, the Brother group has evolved from a single vitamin manufacturer into a diversified pharmaceutical and fine chemical enterprise with a fully integrated industrial ecosystem.Although the three companies operate independently, they are strategically connected through shared technology, coordinated management, and complementary business objectives.The global chemical and pharmaceutical industries are filled with companies that share similar names, but few possess such a clearly defined division of responsibilities and such an effectively integrated industrial structure.Brother Enterprises Holding Co., Ltd., Jiangsu Brother Vitamins Co., Ltd., and Jiangxi Brother Pharmaceutical Co., Ltd. represent three companies, three strategic locations, and one unified vision for long-term industrial development.As global demand continues to grow for vitamins, food ingredients, specialty chemicals, and pharmaceutical APIs, the Brother group is well positioned to leverage its integrated supply chain, advanced manufacturing capabilities, and strong R&D foundation. With its commitment to innovation and quality, this quietly expanding Chinese enterprise is poised to become an increasingly influential force in the global vitamin and specialty pharmaceutical industries. Mobile: +8615371019725E-mail: sales7@bouling-chem.comWebsite: www.brother-pharmaceutical.com

As global demand continues to grow across the feed, food, and pharmaceutical industries, Vitamin B1, Vitamin B3, and Vitamin K3 remain essential nutritional ingredients. Jiangsu Brother Vitamins Co., Ltd. is one of China's leading manufacturers capable of producing all three vitamins on a large commercial scale. Backed by mature synthesis technology, reliable production capacity, and a global supply network, the company has established itself as a trusted long-term supplier for customers around the world.Vitamin B1 (Thiamine)Vitamin B1 plays a vital role in energy metabolism and nervous system function for both humans and animals.In the feed industry, it helps improve nutrient absorption, supports healthy growth, increases survival rates of young animals, and reduces stress. In food applications, Vitamin B1 is widely used to fortify cereals, dairy products, and functional beverages. Pharmaceutical manufacturers use it as an active ingredient in nutritional supplements designed to support energy metabolism and neurological health.Jiangsu Brother Vitamins produces Vitamin B1 that meets Chinese standards as well as internationally recognized FCC and USP specifications. The product features stable crystal morphology, high purity, and excellent processing performance, making it suitable for premixes, food formulations, and pharmaceutical applications.Vitamin B3 (Niacin & Nicotinamide)Vitamin B3 is supplied primarily in two forms: Niacin and Nicotinamide, both of which remain among the highest-demand vitamins in the global market.In animal nutrition, Vitamin B3 promotes healthy skin development, bone growth, and overall livestock performance. Within the food industry, it is commonly used in bakery products, meal replacements, nutritional supplements, and fortified foods. It also serves as an important ingredient in cosmetics, skincare products, and pharmaceutical formulations.Jiangsu Brother Vitamins operates proprietary continuous synthesis production lines that minimize by-products while improving product consistency. The resulting products offer excellent water solubility, uniform appearance between batches, and reliable quality for large-volume supply, earning the trust of major feed manufacturers and food ingredient companies worldwide.Vitamin K3 (Menadione)Vitamin K3 is widely used to regulate blood coagulation and is considered an essential nutritional additive in animal feed as well as an important veterinary pharmaceutical ingredient.Supplementing poultry and livestock feed with Vitamin K3 helps reduce hemorrhagic disorders and improve eggshell quality. In addition, it serves as an intermediate for further pharmaceutical and specialty chemical manufacturing.Compared with conventional production technologies, Jiangsu Brother Vitamins utilizes optimized catalytic processes that significantly reduce heavy metal residues and comply with European feed additive requirements, providing a strong competitive advantage in international markets.As the core raw material production base within the Brother industrial group, Jiangsu Brother Vitamins has developed three major competitive advantages centered on Vitamin B1, Vitamin B3, and Vitamin K3.Integrated Production for Stable CostsThe company manufactures key chemical intermediates internally, reducing dependence on external suppliers and improving cost control. Even during periods of raw material price fluctuations, this integrated production model enables more stable pricing for customers. Intermediate products also support downstream manufacturing within Jiangxi Brother Pharmaceutical, strengthening collaboration throughout the group's supply chain.Large-Scale Intelligent ManufacturingLocated in the Dafeng Chemical Industrial Park in Jiangsu Province, the facility is equipped with standardized clean workshops, automated crystallization systems, screening equipment, and packaging lines. Independent production areas for Vitamins B1, B3, and K3 ensure efficient manufacturing while maintaining consistent quality.With annual production capacity ranking among China's leading manufacturers, the company is capable of fulfilling long-term contracts involving thousands of tons and offers flexible packaging options including bulk shipments, 25 kg bags, and customized packaging.Comprehensive Quality CertificationsThe company's complete vitamin product portfolio is manufactured under rigorous quality management systems and complies with internationally recognized standards, including FCC, USP, and Feed Grade specifications. Products are also registered under REACH, enabling exports to Europe and other global markets.Today, Jiangsu Brother Vitamins supplies thousands of domestic customers while exporting to Southeast Asia, Europe, South America, the Middle East, and many other international markets.Environmental performance has become an increasingly important factor in vitamin manufacturing.To improve sustainability, Jiangsu Brother Vitamins has optimized production technologies for all three vitamin products by adopting cleaner catalytic processes that replace traditional high-pollution oxidation methods. The company also operates comprehensive waste gas treatment and wastewater recycling systems, earning recognition as an environmentally responsible enterprise within its industrial park.Its manufacturing standards deliver high purity, low residual impurities, and consistent product quality that satisfy both Chinese regulatory requirements and stringent international import standards.Many suppliers specialize in only one vitamin product, requiring customers to source multiple ingredients from different manufacturers, increasing purchasing complexity and logistics costs.Jiangsu Brother Vitamins simplifies procurement by supplying Vitamin B1, Vitamin B3, and Vitamin K3 from a single manufacturing base. Customers benefit from consolidated shipments, unified quality documentation, coordinated after-sales support, and streamlined purchasing, making the company an ideal partner for feed premix manufacturers, food ingredient distributors, and pharmaceutical companies.From animal nutrition and food fortification to pharmaceutical manufacturing, demand for Vitamins B1, B3, and K3 continues to grow worldwide.By focusing on these three essential vitamins, Jiangsu Brother Vitamins Co., Ltd. has built a strong reputation through large-scale manufacturing, advanced production technology, integrated supply chain management, and rigorous quality control.As global supply chains continue to diversify, the company is well positioned to provide reliable, internationally compliant vitamin ingredients, strengthening the presence of Chinese manufacturers in the global vitamin market. Mobile: +8615371019725E-mail: sales7@bouling-chem.comWebsite: www.brother-pharmaceutical.com

Within China's vitamin, specialty API, and pharmaceutical formulation industries, the Brother Group has established two key business pillars: Brother Enterprises Holding Co., Ltd., the group's strategic holding platform, and Zhejiang Brothers Pharmaceutical Co., Ltd., its dedicated pharmaceutical formulation company. Together, they form the backbone of Brother's integrated healthcare strategy, connecting upstream raw material manufacturing with downstream finished pharmaceutical products.Founded in 1991 in Haining, Zhejiang Province, Brother Enterprises Holding Co., Ltd. serves as the parent company of the Brother Group. Listed on the Shenzhen Stock Exchange in 2011 (Stock Code: 002562), the company oversees the group's worldwide operations, including manufacturing, research and development, investment, and international business expansion.Strategic Management Across the Entire GroupBrother Enterprises Holding manages six major business divisions covering vitamins, pharmaceutical ingredients, flavors and fragrances, leather chemicals, catalysts, and chromium chemicals.The group operates large-scale manufacturing bases in Zhejiang, Jiangsu, Jiangxi, and South Africa. Subsidiaries including Jiangsu Brother Vitamins Co., Ltd., Jiangxi Brother Pharmaceutical Co., Ltd., and Zhejiang Brothers Pharmaceutical Co., Ltd. are all wholly owned by the parent company.Rather than participating directly in manufacturing, the holding company is responsible for corporate strategy, capital investment, global supply chain management, regulatory compliance, international market development, and long-term capacity planning, serving as the decision-making center for the entire organization.A Strong Foundation in Raw Material ManufacturingSupported by its production facilities in Zhejiang and Jiangsu, the group has established large-scale manufacturing capabilities for Vitamin B1, Vitamin B3, Vitamin K3, iodinated contrast media intermediates, vanillin, and other specialty chemical products.These products serve customers across the feed, food, pharmaceutical, and fine chemical industries throughout Europe, North America, Southeast Asia, the Middle East, and many other international markets.Because many key raw materials are produced internally, downstream pharmaceutical subsidiaries benefit from reliable supply, competitive costs, and enhanced manufacturing efficiency through vertical integration.Integrated Research and DevelopmentBrother Enterprises Holding has established a three-level innovation system consisting of a corporate research institute, technology centers at each manufacturing base, and specialized business-unit R&D teams.Working closely with leading universities and research institutes, the group focuses on green synthesis technologies, pharmaceutical purification, process optimization, and formulation development. Research成果 are shared across the organization, providing Zhejiang Brothers Pharmaceutical with both advanced technologies and high-quality intermediates for pharmaceutical product development.Established in 2018 and located in Qiantang, Zhejiang Province, Zhejiang Brothers Pharmaceutical Co., Ltd. is a wholly owned subsidiary dedicated to pharmaceutical formulations.Its creation marked an important milestone in the Brother Group's development by extending its business beyond APIs and chemical intermediates into finished pharmaceutical products, completing the final stage of the pharmaceutical value chain.Completing the API-to-Formulation Value ChainWhile the Jiangsu and Jiangxi manufacturing bases specialize in vitamins, intermediates, and APIs, Zhejiang Brothers Pharmaceutical focuses on pharmaceutical formulation development, product registration, manufacturing, and commercialization.Leveraging the group's internally produced vitamins and specialty APIs, the company develops oral nutritional products, dietary supplements, and specialty pharmaceutical formulations covering neurological health, metabolic support, and nutritional supplementation.This integrated model allows Brother to combine in-house API manufacturing with proprietary finished dosage forms, creating a complete pharmaceutical ecosystem.Building a Comprehensive Product PipelineThe company is developing multiple pharmaceutical dosage forms, including tablets, capsules, and oral liquid formulations.With more than twenty products currently under development, several have already entered China's regulatory registration process, while additional formulation products are being prepared for international registration through the group's global marketing network.The company has also established several biotechnology research subsidiaries dedicated to innovative generic pharmaceuticals, nutritional healthcare products, and future pharmaceutical innovation projects.Strong Internal SynergiesThe integration between Brother Enterprises Holding and Zhejiang Brothers Pharmaceutical creates significant operational advantages.Upstream, Jiangsu Brother Vitamins and Jiangxi Brother Pharmaceutical provide a stable supply of high-purity Vitamin B1, Vitamin B3, Vitamin K3, iodinated contrast media APIs, and other specialty ingredients, eliminating dependence on external suppliers and improving production cost control.Throughout manufacturing, the company benefits from the group's unified quality assurance, environmental protection, and safety management systems while complying with international standards including ISO, FCC, USP, and REACH requirements where applicable.Downstream, finished pharmaceutical products can utilize the group's established domestic and international sales network, reducing market entry costs and accelerating commercialization.Many chemical manufacturers remain focused solely on raw materials and struggle to enter higher-value pharmaceutical formulation markets.Brother has addressed this challenge through a business structure that combines centralized strategic management with specialized pharmaceutical development.Clearly Defined ResponsibilitiesBrother Enterprises Holding oversees capital investment, manufacturing resources, raw material production, and global market development, building a competitive foundation through large-scale integrated manufacturing.Zhejiang Brothers Pharmaceutical concentrates on formulation research, pharmaceutical registration, product development, and commercial sales, allowing the group to expand into higher-margin pharmaceutical markets.Together, these complementary roles create a balanced and sustainable business model.Stronger Resilience Through Vertical IntegrationWhen raw material prices fluctuate, internal manufacturing helps stabilize production costs for pharmaceutical formulations.At the same time, higher-value finished pharmaceutical products provide stronger profitability, helping offset cyclical fluctuations in commodity vitamin markets and improving the group's long-term financial stability.Regional Collaboration in ZhejiangBoth the corporate headquarters in Haining and the pharmaceutical formulation base in Qiantang are located within Zhejiang Province, enabling efficient collaboration in talent development, research, logistics, and regulatory coordination.Supported by Zhejiang's strong life sciences ecosystem and favorable industrial policies, the group continues to increase investment in pharmaceutical innovation while strengthening its integrated vitamin and pharmaceutical manufacturing platform.Global demand continues to expand for animal nutrition, dietary supplements, and specialty pharmaceuticals. As profit margins for commodity raw materials become increasingly competitive, vertical integration from APIs to finished formulations has become an important direction for industry development.With Brother Enterprises Holding providing strategic leadership, Zhejiang Brothers Pharmaceutical driving pharmaceutical formulation development, and Jiangsu Brother Vitamins together with Jiangxi Brother Pharmaceutical supplying high-quality raw materials and APIs, the Brother Group has established a complete industrial chain covering upstream fine chemicals, pharmaceutical ingredients, and downstream finished dosage forms.Going forward, the group plans to continue expanding pharmaceutical research and development, enrich its formulation pipeline, and leverage its international business network to introduce more Chinese-made vitamin formulations and specialty pharmaceutical products to global markets.Brother Enterprises Holding Co., Ltd. represents more than three decades of industrial experience, providing strategic leadership and an integrated manufacturing foundation for the entire group.Zhejiang Brothers Pharmaceutical Co., Ltd. serves as the group's platform for pharmaceutical innovation, transforming internally produced APIs into high-value finished medicines and healthcare products.Together, these two companies demonstrate how centralized strategic management combined with specialized pharmaceutical development creates a fully integrated business model. Their close collaboration across raw materials, APIs, and finished formulations continues to strengthen the Brother Group's position as one of China's leading manufacturers in the global vitamin and pharmaceutical industries. Mobile: +8615371019725E-mail: sales7@bouling-chem.comWebsite: www.brother-pharmaceutical.com

Within the integrated industrial ecosystem of Brother Enterprises Holding Co., Ltd., Zhejiang Brothers Pharmaceutical Co., Ltd. serves as the group's dedicated platform for the research, registration, commercialization, and marketing of pharmaceutical formulations. Unlike the Jiangsu and Jiangxi production bases, which specialize in vitamins and active pharmaceutical ingredients (APIs), Zhejiang Brothers Pharmaceutical focuses on finished dosage forms, leveraging the group's internally manufactured APIs to build a diversified portfolio covering diagnostic imaging, cardiovascular disease, neurology, metabolic disorders, and nutritional supplementation.By integrating API manufacturing with formulation development, the company completes Brother's "API-to-formulation" value chain and strengthens its position in the pharmaceutical industry.Leveraging the group's in-house production of Iohexol and Iopamidol APIs at Jiangxi Brother Pharmaceutical, Zhejiang Brothers Pharmaceutical has successfully developed multiple contrast media injection products widely used in hospitals for CT enhancement and radiographic examinations.Iohexol InjectionAvailable in multiple iodine concentrations and packaging sizes, including 50 mL and 100 mL presentations, Iohexol Injection is a non-ionic, low-osmolar contrast medium indicated for contrast-enhanced CT imaging, angiography, and urography. The product offers excellent clinical safety and has been included in China's centralized volume-based procurement program.Iopamidol InjectionIopamidol Injection is a Class A product under China's national medical insurance system and is widely used in cerebral angiography, cardiovascular imaging, spinal examinations, and arthrography. Featuring low viscosity and excellent patient tolerance, the product received commercial approval in 2025, expanding the group's portfolio of premium diagnostic imaging products.Because both APIs are manufactured internally within the Brother Group, Zhejiang Brothers Pharmaceutical benefits from greater cost control, stable supply, and enhanced competitiveness in both domestic and international markets.The company has developed several oral formulations targeting chronic cardiovascular diseases such as hypertension and coronary artery disease. Multiple products are covered by China's medical insurance system and centralized procurement program, serving hospitals, healthcare institutions, and retail pharmacy chains.Bisoprolol Fumarate TabletsBisoprolol Fumarate is a selective beta-blocker indicated for hypertension, angina pectoris, and chronic heart failure. The company's 5 mg formulation has passed China's generic consistency evaluation and is widely prescribed in clinical practice.Tranexamic Acid TabletsTranexamic Acid Tablets are hemostatic agents used to control bleeding associated with surgery and systemic hyperfibrinolysis. The product is commonly utilized in surgical, gynecological, and other clinical settings.Recognizing the growing demand for neurological therapies, Zhejiang Brothers Pharmaceutical has expanded its pipeline to include treatments for epilepsy, Parkinson's disease, and other neurological disorders.Lacosamide InjectionLacosamide Injection is a third-generation antiepileptic therapy indicated for adjunctive treatment of partial-onset seizures in patients aged four years and older. The product is covered by China's national medical insurance program and has been selected for the country's tenth round of centralized procurement.Safinamide Mesylate Tablets (Under Development)Safinamide Mesylate is an innovative therapy for Parkinson's disease. The product has completed bioequivalence studies and represents an important addition to the company's pipeline targeting neurodegenerative diseases affecting aging populations.The company is also expanding into treatments for hyperuricemia and gout, strengthening its presence in metabolic disease therapeutics.Topiroxostat TabletsTopiroxostat is a novel xanthine oxidase inhibitor used to lower serum uric acid levels in patients with gout and hyperuricemia. Zhejiang Brothers Pharmaceutical has completed bioequivalence studies and is progressing toward regulatory approval. Once commercialized, the formulation will utilize Topiroxostat APIs manufactured within the Brother Group, further enhancing vertical integration.Building upon the group's long-established expertise in Vitamin B1 and Vitamin B3 manufacturing, Zhejiang Brothers Pharmaceutical has introduced nutritional formulations for both prescription and over-the-counter markets.Vitamin B1 Tablets (10 mg)Vitamin B1 Tablets are indicated for the prevention and treatment of Vitamin B1 deficiency, peripheral neuritis, digestive disorders, and fatigue associated with insufficient vitamin intake. Because the active ingredient is manufactured internally by the group, the company maintains stable product quality and secure raw material supply.In addition to its marketed products, Zhejiang Brothers Pharmaceutical maintains a pipeline of more than twenty pharmaceutical products currently under development.The pipeline includes tablets, capsules, oral liquids, and small-volume injections covering respiratory diseases, gastrointestinal disorders, dermatology, and additional therapeutic areas.The company follows China's Marketing Authorization Holder (MAH) system, outsourcing commercial manufacturing to qualified pharmaceutical manufacturers while concentrating its own resources on formulation research, process development, regulatory registration, and product commercialization. This asset-light strategy enables faster product launches while maximizing research efficiency.Reliable API SupplyKey APIs including Iohexol, Iopamidol, Vitamin B1, and Topiroxostat are supplied directly by the group's manufacturing facilities in Jiangsu and Jiangxi. Internal sourcing reduces procurement costs, improves supply stability, and strengthens pricing competitiveness compared with formulation companies that rely entirely on external API suppliers.Shared Commercial NetworkThe group's established global distribution channels for vitamins, food ingredients, and pharmaceutical raw materials provide a strong foundation for future formulation exports. Within China, the company also benefits from long-term partnerships with pharmaceutical distributors, retail pharmacy chains, and leading hospitals.Shared Research ResourcesZhejiang Brothers Pharmaceutical has access to the group's centralized research institute, pilot-scale manufacturing platforms, and API process technologies. By integrating API development with formulation research, the company shortens development timelines and improves formulation optimization.Unlike the group's manufacturing subsidiaries that specialize in bulk vitamins, specialty chemicals, and APIs, Zhejiang Brothers Pharmaceutical focuses exclusively on finished pharmaceutical products.The company represents a critical step in Brother Enterprises Holding's transformation from a manufacturer of pharmaceutical ingredients into a fully integrated pharmaceutical enterprise combining APIs and finished dosage forms.Its growing portfolio addresses essential healthcare needs in diagnostic imaging, chronic disease management, neurology, metabolic disorders, and nutritional supplementation, while a robust development pipeline supports long-term growth.From diagnostic imaging injections to oral therapies for chronic diseases, and from established commercial products to an expanding portfolio of innovative generic medicines, Zhejiang Brothers Pharmaceutical continues to strengthen its position in China's pharmaceutical formulation industry.Supported by Brother's fully integrated industrial chain, the company combines internal API manufacturing, shared research capabilities, and an extensive commercial network to create sustainable competitive advantages. As generic drug consistency evaluation and centralized procurement continue to reshape China's pharmaceutical market, this vertically integrated business model positions Zhejiang Brothers Pharmaceutical for continued domestic and international growth. Mobile: +8615371019725E-mail: sales7@bouling-chem.comWebsite: www.brother-pharmaceutical.com

In the specialty chemicals industry, competitive advantage is built on three fundamental pillars: resource security, technological expertise, and supply chain integration. For Brother Technology Co., Ltd., the acquisition of BROTHER CISA (PTY) LTD (CISA) in South Africa in 2020 was far more than an overseas investment—it was a long-term strategic move designed to strengthen upstream capabilities and reinforce the company's global industrial foundation.By integrating a century-old chromium chemicals manufacturer with German technological heritage, Brother Technology successfully completed its chromium chemicals value chain, achieving vertical integration and significantly enhancing its competitiveness in the global specialty chemicals market.Located in Newcastle, South Africa, BROTHER CISA operates on approximately 500 mu (about 33 hectares) of industrial land and carries more than 100 years of experience in chromium chemicals manufacturing.Originally part of the global specialty chemicals company Lanxess, CISA inherited German manufacturing standards, mature production technologies, rigorous quality management systems, and comprehensive regulatory qualifications.Its primary products include:Sodium DichromateChromic AcidChromium Tanning AgentsThese products serve as essential raw materials for leather processing, pharmaceutical catalysts, pigments, and, most importantly, the production of Vitamin K3, one of Brother Technology's flagship products.Chromium chemicals remain one of the most highly regulated sectors within the specialty chemical industry due to stringent environmental requirements, demanding production technologies, and concentrated resource distribution. Since South Africa possesses the majority of the world's chromite reserves, compliant large-scale chromium chemical assets are exceptionally scarce.Before the acquisition, CISA had already established itself as one of the industry's most valuable chromium chemical production bases, combining abundant mineral resources, German engineering excellence, and decades of operational expertise.Prior to the acquisition, Brother Technology had already become a global leader in Vitamin K3 and an important supplier of leather chemicals. However, the company still faced two significant industry-wide challenges:Upstream Raw Material DependenceSodium dichromate is the key raw material for producing both Vitamin K3 and chromium tanning agents. Relying on external suppliers exposed the company to volatile raw material prices, supply instability, and international logistics risks.Limited Domestic Capacity ExpansionChina's increasingly stringent environmental regulations made approvals for new chromium chemical production capacity extremely difficult. This restricted opportunities for upstream expansion while leaving manufacturers vulnerable to fluctuating supplier pricing.To address these structural challenges, Brother Technology acquired 100% of CISA from Lanxess for approximately RMB 660 million.Rather than pursuing short-term production expansion, the acquisition fundamentally transformed the company's supply chain by internalizing a critical upstream resource and improving long-term operational certainty.Unlike many international acquisitions that focus solely on expanding production capacity, Brother Technology's acquisition of CISA established a fully integrated industrial chain linking chromium chemicals with specialty chemicals and Vitamin K3 production.1. Resource Advantages and Lower Production CostsSouth Africa possesses some of the world's richest chromite resources, allowing CISA to source raw materials locally while significantly reducing transportation expenses.Additional cost advantages include:Raw material procurement costs approximately 15–20% lower than comparable domestic operationsLocal electricity prices roughly one-third of those in ChinaAnnual production capacity of approximately 76,000 metric tons of sodium dichromateThese advantages substantially strengthen Brother Technology's upstream supply security while reducing overall production costs.2. German Technology Strengthens Manufacturing ExcellenceCISA inherited advanced chromium chemical manufacturing technologies developed under Lanxess, particularly in:Product purity controlImpurity managementStable production processesConsistent product qualityHigher-purity chromium chemicals enable applications in pharmaceuticals, premium leather processing, and other high-value specialty chemical markets.The acquisition also enhanced Brother Technology's integrated production model. Through its proprietary co-production technology, the company can produce approximately 15 tons of chromium tanning agents alongside every 1 ton of Vitamin K3, maximizing resource utilization while reducing unit production costs.This integrated manufacturing capability creates a significant technological barrier that is difficult for competitors to replicate.3. Global Supply Chain SynergyThe acquisition delivers benefits across both domestic and international markets.For Brother Technology's Chinese manufacturing facilities, CISA provides a stable internal supply of sodium dichromate, ensuring reliable production of Vitamin K3 and leather chemicals while minimizing exposure to commodity price volatility.Internationally, CISA's South African production base serves customers throughout:AfricaEuropeThe Middle EastIts strategic location also helps mitigate trade barriers and strengthens Brother Technology's global sales network.Today, the company has become China's largest producer of chromium tanning agents and the world's third-largest producer, further solidifying its international market position.Following several years of successful integration, Brother Technology's specialty chemicals business has become one of the company's major revenue contributors, generating RMB 1.243 billion in revenue in 2025, demonstrating the long-term value created by this strategic acquisition.As more Chinese specialty chemical companies expand internationally, many focus primarily on contract manufacturing or relocating production capacity overseas.Brother Technology has chosen a different path.Instead of simply adding overseas facilities, the company acquired a high-quality strategic asset with over a century of manufacturing experience, advanced technologies, valuable mineral resources, and internationally recognized operational systems.The acquisition transformed Brother Technology from a company dependent on external chromium chemical suppliers into one controlling critical upstream resources, operating an integrated production chain, and serving customers worldwide.The resulting improvements in supply security, production efficiency, technological capability, and cost competitiveness have become essential strengths that support sustainable growth throughout industry cycles.In the chemical industry, lasting success is never achieved through shortcuts. It is built through continuous investment in technology, supply chain integration, and industrial capabilities.With South Africa as a strategic foundation and global markets as its destination, Brother Technology will continue strengthening the operation of its overseas assets, expanding its chromium chemicals business, and advancing its position as a leading global specialty chemicals manufacturer. Mobile: +8615371019725E-mail: sales7@bouling-chem.comWebsite: www.brother-pharmaceutical.com